Terms: = Liver cancer AND DNAJB1, HSPF1, 3337, ENSG00000132002, P25685, Hdj1, Hsp40 AND Diagnosis
12 results:
1. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract] [Full Text] [Related]
3. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract] [Full Text] [Related]
4. Fibrolamellar carcinoma: An entity all its own.
O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K
Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087
[TBL] [Abstract] [Full Text] [Related]
5. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract] [Full Text] [Related]
6. dnajb1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract] [Full Text] [Related]
7. Update on the pathology of liver neoplasms.
Matsukuma KE; Yeh MM
Ann Diagn Pathol; 2019 Feb; 38():126-137. PubMed ID: 30597357
[TBL] [Abstract] [Full Text] [Related]
8. Fibrolamellar Carcinoma: What Is New and Why It Matters.
Graham RP
Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
[TBL] [Abstract] [Full Text] [Related]
9. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract] [Full Text] [Related]
10. dnajb1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract] [Full Text] [Related]
11. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic imaging and interventional therapy of hepatocellular carcinoma.
Palma LD
Br J Radiol; 1998 Aug; 71(848):808-18. PubMed ID: 9828792
[TBL] [Abstract] [Full Text] [Related]